Genetic Engineering News Publishes List of Top 20 Molecular Millionaires

Business Wire, May 30, 2006

NEW ROCHELLE, N.Y. -- Arthur Levinson, Ph.D., chairman and CEO of Genentech, heads the list of GEN's Top 20 Molecular Millionaires for 2006, reports Genetic Engineering News (GEN); www.genengnews.com. The list, which is published annually, is in the June 1 issue of GEN and on the website at www.genengnews.com. [R][sup.3]"Scientists and commerce can go very well together," says John Sterling, Editor-in-Chief of GEN. "And their careers have staying power, despite the ups and downs that the biotech and pharmaceutical industries regularly experience. For scientists or would-be scientists, those who choose to pursue biotech careers can wind up fabulously wealthy." In addition to naming these molecular millionaires, GEN provides biographical sketches of these molecular millionaires and their words of wisdom for wannabes. [R][sup.3]Dr. Levinson, for example, taught himself the intricacies of the stock market while still in college, a move that certainly helped him reach the pinnacle of business success at Genentech. His advice: "Convince entrepreneurs to work for you. Hire top scientists."

[R][sup.3]The complete list of GEN's Top 20 Molecular Millionaires for 2006 includes: Arthur Levinson, Ph.D., Genentech (NYSE:DNA, South San Francisco, CA); John Martin, Ph.D., Gilead Sciences (NASDAQ:GILD, Foster City, CA); William A. Haseltine, Ph.D., Human Genome Sciences (NASDAQ:HGSI, Rockville, MD); Sol J. Barer, Ph.D., Celgene (NASDAQ:CELG, Warren, NJ); Wayne T. Hockmeyer, Ph.D., MedImmune (NASDAQ:MEDI, Gaithersburg, MD); Leonard Schleifer, M.D, Ph.D., Regeneron Pharmaceuticals (NASDAQ:REGN, Tarrytown, NY); Orville G. Kolterman, Ph.D., Amylin Pharmaceuticals (NASDAQ:AMLN, San Diego, CA); Paul J. Maddon, M.D., Ph.D., Progenics Pharmaceuticals (NASDAQ:PGNX, Tarrytown, NY); Leonard Bell, M.D., Alexion Pharmaceuticals (NASDAQ:ALXN, Cheshire, CT); Mark H. Skolnick, Ph.D., Myriad Genetics (NASDAQ:MYGN, Salt Lake City, UT); Elliot Hahn, Ph.D., Andrx Corp. (NASDAQ:ADRX, Davie, FL); Elazar Rabbani, Ph.D., Enzo Biochem (NYSE:ENZ, Farmingdale, NY); Bruce L.A. Carter, Ph.D., ZymoGenetics (NASDAQ:ZGEN, Seattle, WA); David M. Goldenberg, Sc.D., M.D., Immunomedics (NASDAQ:IMMU, Morris Plains, NJ); Arthur T. Sands, M.D., Ph.D., Lexicon Genetics (NASDAQ:LEXG, The Woodlands, TX); Russell Howard, Ph.D., Maxygen (NASDAQ:MAXY, Redwood City, CA); Henry Y. Pan, M.D., Ph.D., Neurocrine Biosciences (NASDAQ:NBIX, San Diego, CA); Gary Wilcox, Ph.D., Icos Corp. (NASDAQ:ICOS, Bothell, WA); Dominic P. Behand, Ph.D., Arena Pharmaceuticals (NASDAQ:ARNA, San Diego, CA), and Edward Penhoet, Ph.D., Chiron* (NYSE:NVS, Emeryville, CA). [R][sup.3]*Chiron shareholders recently approved the acquisition of the company by Novartis AG (NYSE:NVS).

[R][sup.3]Genetic Engineering News, which is published 21 times a year by Mary Ann Liebert, Inc., is the most widely-read biotechnology news magazine worldwide. It includes articles on Drug Discovery, Bioprocessing, Omics, and Translational Medicine and covers applied research through commercialization and the business of biotechnology. [R][sup.3]For a print copy of the June 1 issue of Genetic Engineering News, call (914) 740-2122, or email: ebicovny@liebertpub.com.